Stomach Carcinoma
|
0.400 |
GenomicAlterations
|
disease |
CGI |
|
|
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis.
|
24223894 |
2013 |
Stomach Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MET rs40239 may serve as a prognostic biomarker in locoregional gastric cancer.
|
25203738 |
2014 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MET-positive GCs had a very poor prognosis, with a median survival of 5.4 months and a hazard ratio of 2.126.
|
26033401 |
2016 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
c-Met targeting in advanced gastric cancer: An open challenge.
|
26049023 |
2015 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MET amplification has been clinically credentialed as a therapeutic target in gastric cancer, but the molecular mechanisms underlying sensitivity and resistance to MET inhibitors are still not well understood.
|
28881678 |
2017 |
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MET amplification and Met overexpression were positively correlated in GC.
|
29790169 |
2018 |
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MET is overexpressed in microsatellite instability-high gastric carcinoma.
|
30455128 |
2019 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A multivariate analysis suggested that MET positivity may still be prognostic for worse median overall survival in gastric cancer; therefore, it is important to continue investigation into the optimal approach to inhibit MET signaling in gastric cancer.
|
27401892 |
2016 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
|
30511201 |
2019 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Also, the prognostic role of MET indicates that anti-MET therapy is a very promising modality in adjuvant treatment for gastric cancer.
|
22644302 |
2012 |
Stomach Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Approximately 10 - 20% of gastric cancer presented an increased MET gene copy numbers; inappropriate activation of MET promotes cellular proliferation, cell motility, invasiveness and angiogenesis and is associated with more aggressive phenotype and with a lower survival.
|
25881479 |
2015 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Candidate tumor suppressor genes at FRA7G are coamplified with MET and do not suppress malignancy in a gastric cancer.
|
12620387 |
2003 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Comprehensive genomic profiling of GC identifies clinically relevant GAs that suggest benefit from targeted therapy including MET-amplified GC and ERBB2 base substitutions.
|
25882375 |
2015 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Crizotinib may induce clinically relevant anticancer effects in MET-overexpressed or MET-amplified gastric cancer patients.
|
26404902 |
2016 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric Cancer.
|
27185371 |
2016 |
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression.
|
25584489 |
2015 |
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression of gastrin and c-met protein was associated (P<0.01), but no significant difference was found on the changes of gastrin, c-met and c-erbB2 expression in gastric cancer with tumor stage, grade of differentiation or tumor type.
|
14719064 |
2004 |
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, we observed an inverse correlation between the expression of miR-144 and MET mRNA in GC metastatic tissues.
|
25927670 |
2015 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Four c-MET inhibitors were tested to elucidate the dependency on MET pathway in the 49 GC cell lines.
|
29435981 |
2018 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, the profile of the gastric cancer samples observed that sf-RON was frequently upregulated in MET-positive gastric cancer.
|
26528757 |
2015 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we show that BFB cycles drive the intrachromosomal amplification of the MET oncogene in a human gastric carcinoma.
|
12086891 |
2002 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target.
|
21424128 |
2011 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation.
|
27437872 |
2016 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In 123 cases with primary and corresponding local recurrent/distant metastatic GC, 3 (2.4%) showed MET positivity in which 2 (66.7%) were discordant (positive conversion).
|
28968267 |
2018 |